Offering HIV prevention pills alongside opioid replacement treatment at pharmacies
Tests whether pharmacies can offer HIV prevention pills with opioid replacement treatment.
Plain-language title generated from the registry record
Registry title: HIV Prevention With PrEP Among People on Opioid Replacement Therapy
Key facts
- Where
- Calgary, Regina, and Saskatoon, CanadaSee the 6 sites
- Phase
- Phase 4
Where in Canada
- Sheldon M. Chumir Health CentreCalgary, CanadaNot yet recruiting
- Queen City Wellness PharmacyRegina, CanadaNot yet recruiting
- Mayfair Drugs PharmacySaskatoon, CanadaTaking people
- Meadowgreen PharmacySaskatoon, CanadaTaking people
- Pharmasave Riversdale PharmacySaskatoon, CanadaTaking people
- The Medicine Shoppe PharmacySaskatoon, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cara Spence
- Trial code
- NCT07160075
- Record updated
- 7 October 2025
- Original description
The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta and Saskatchewan, to collect preference, adherence, and persistence data on oral PrEP, and to assess interest / acceptability of long-lasting injectable options for human immunodeficiency virus (HIV) prevention.Read full original descriptionShow less
Improving Access to HIV Pre-exposure Prophylaxis: Implementation and Evaluation of Innovative HIV Prevention Services Among Persons on Opioid Replacement Therapy in Western Canada: Prospective, Implementation Study
The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta and Saskatchewan, to collect preference, adherence, and persistence data on oral PrEP, and to assess interest / acceptability of long-lasting injectable options for human immunodeficiency virus (HIV) prevention.
Inclusion: HIV negative; Ongoing behaviors with potential HIV exposure as assessed by a clinician; Regularly engaged with their respective OAT program at least 3 days a week for the past 2 weeks; Report willingness to return for follow-up visits.
Exclusion: Deemed appropriate by a clinician for HIV Post-Exposure Prophylaxis at the time of screening or enrollment; Creatine clearance <30 mL/min or any medical condition or medication known to be contraindicated with the use of Emtricitabine/Tenofovir Alafenamide (F/TAF) or Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF); Taken PrEP within the last 24 hours at the time of screening or enrollment.